Intercos S.p.A.: Innovation-Led Orders and Cost Pass-Through Underpin Confident FY26 Outlook

Core Thesis

Intercos' 1Q26 reported constant-currency sales growth of -6.3% slightly missed Visible Alpha consensus of -5.1%, but adjusted EBITDA came in 4% ahead. Management maintained a confident FY26 outlook: reported sales growth of +5-6% (consensus +5.3%), supported by a 10% year-on-year increase in order intake (makeup/skincare) over the last six months. The key qualitative nuance—orders are increasingly skewed toward new product innovation (35% of orders vs. typical 30%)—was explicitly confirmed by management as not driven by supply-security pull-forwards. We believe the current price of €11.84 does not fully reflect this improvement in order quality or the company's demonstrated pricing power. Reiterate Overweight with a €15.00 target price, implying 26.7% upside.

What the Market May Be Underestimating

The market appears focused on the 120bp top-line miss versus consensus, but this ignores two structural shifts:

• Order mix improvement: The proportion of innovation orders exceeds historical norms, which management attributes to genuine end-demand and brand innovation cycles. This is a leading indicator of future reorder momentum.
• Cost pass-through resilience: Logistics accounts for only 2.5% of COGS; the company has already communicated monthly surcharges to clients. Energy costs are fully fixed for FY26. Intercos' small share of customers' COGS and proprietary formula IP support bargaining power—a dynamic not fully priced into near-term margin expectations.
• Macro recovery acceleration: Global beauty market growth forecast was raised from ~4% to 4-5% for 2026, with US volume growth of ~3% (a notable improvement versus a year ago) and China supported by the upcoming 6.18 event.

Evidence Chain

1. Strong Order Intake Is Innovation-Driven, Not Inventory Buildup

• Orders in makeup/skincare grew 10% year-on-year in the last six months. Innovation products comprised ~35% of orders (typical run-rate ~30%).
• Management explicitly stated it sees no evidence of clients ordering ahead for supply security, attributing the strength to innovation pushes among Western prestige brands in Europe and the US.
• Hair & Body forecasts are also robust (notably fragrances), with order intake not fully captured in the reported figure.
• Investment implication: This suggests organic demand momentum rather than channel fill, reducing the risk of order reversals through 2026.

2. Cost Pressures Are Manageable and Already Being Passed On

• Logistics costs represent ~2.5% of COGS; Intercos has limited outbound cost exposure (clients typically collect their own orders). The company has communicated monthly surcharges to customers.
• Energy costs are fixed for the full year and therefore will not affect FY26 margins.
• Investment implication: Margin expansion of +24bp (adj. EBITDA margin: 15.2% FY26E, consensus 15.0%) appears achievable without material headwind from logistics or energy.

3. Global Beauty Market Recovery Is Broadening

• Intercos raised its 2026 global beauty market growth estimate from ~4% to 4-5%, citing gradual improvement in US volumes (+3% volume growth vs. flat a year ago) driven by innovations from multinational brands that were developed over the last ~18 months.
• China started positively, sustained primarily by prestige skincare; the 6.18 event will be a key confirmatory data point. EMEA is progressing in line with expectations.
• Investment implication: A stronger macro backdrop supports Intercos' top-line guidance (5-6% reported growth) and provides upside optionality if momentum continues.

Key Risks

• Macro-economic pressure could cause client order delays or cancellations, particularly if consumer demand weakens.
• CFO departure introduces near-term operational uncertainty; the company has initiated a search and appointed current COO Vittorio Brenna as interim CFO.
• Cost cost overruns (raw materials or logistics) beyond current expectations, if pass-through proves insufficient.
• Customer concentration: Loss of a major client or contract could materially impact revenue.

Valuation and Trade Implication

Our price target of €15.00 is a rounded average of:

• DCF valuation at €14.5 (WACC 9.8%, terminal growth +2.5%, implied ~9x 2026E EV/EBITDA)
• Multiples approach at €15.5 (9x 2026E EV/EBITDA, a ~30% discount to ingredients peers, justified by quarterly earnings volatility and product concentration)

Current share price: €11.84. Net debt at end-2026E: €121mn, EV ~€1,258mn. Upside of 26.7% supports Overweight.

Appendix: Key Financial Summary